Differential Dependence on Host Cell Glycosaminoglycans for Infection of Epithelial Cells by High-Risk HPV Types

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Cruz, Linda ^a   Meyers, Craig ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; KERATINOCYTE; MALE; NONHUMAN; SULFATION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WART VIRUS;

CARRAGEENAN; CELL LINE; CHLORATES; FEMALE; GLYCOSAMINOGLYCANS; HEPARIN; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 31; HUMANS; KERATINOCYTES; SPECIES SPECIFICITY; VIRUS ATTACHMENT; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84879831306     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068379     Document Type: Article

References (47)

1. Schiffman M, Kjaer SK (2003) Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr: 14-19.
2. zur Hausen H, (2009) Papillomaviruses in the causation of human cancers- a brief historical account. Virology 384: 260-265.
3. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M, (2001) Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75: 1565-1570.
4. Culp TD, Budgeon LR, Christensen ND, (2006) Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology 347: 147-159.
5. Pereira R, Hitzeroth, II, Rybicki EP, (2009) Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch Virol 154: 187-197.
6. Finnen RL, Erickson KD, Chen XS, Garcea RL, (2003) Interactions between papillomavirus L1 and L2 capsid proteins. J Virol 77: 4818-4826.
7. Zhao KN, Sun XY, Frazer IH, Zhou J, (1998) DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243: 482-491.
8. Yang R, Day PM, Yutzy WHt, Lin KY, Hung CF, et al. (2003) Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol 77: 3531-3541.
9. Yang R, Yutzy WHt, Viscidi RP, Roden RB, (2003) Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem 278: 12546-12553.
10. Kamper N, Day PM, Nowak T, Selinka HC, Florin L, et al. (2006) A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 80: 759-768.
11. Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, et al. (2012) The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 7: e43519.
12. Doorbar J, (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110: 525-541.
13. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, et al. (2006) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2: e69.
14. Luciani S, Jauregui B, Kieny C, Andrus JK, (2009) Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries. Immunotherapy 1: 795-807.
15. Meyers C, Mayer TJ, Ozbun MA, (1997) Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol 71: 7381-7386.
16. McLaughlin-Drubin ME, Wilson S, Mullikin B, Suzich J, Meyers C, (2003) Human papillomavirus type 45 propagation, infection, and neutralization. Virology 312: 1-7.
17. Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, et al. (2009) Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol 83: 10515-10526.
18. Meyers C, Frattini MG, Hudson JB, Laimins LA, (1992) Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257: 971-973.
19. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78: 751-757.
20. Sapp M, Bienkowska-Haba M, (2009) Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. Febs J 276: 7206-7216.
21. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM, (2009) The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 106: 20458-20463.
22. Culp TD, Budgeon LR, Marinkovich MP, Meneguzzi G, Christensen ND, (2006) Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol 80: 8940-8950.
23. Cerqueira C, Liu Y, Kuhling L, Chai W, Hafezi W, et al. (2013) Heparin increases the infectivity of Human Papillomavirus Type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cell Microbiol.
24. Richards RM, Lowy DR, Schiller JT, Day PM, (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103: 1522-1527.
25. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT, (2008) Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 82: 4638-4646.
26. Selinka HC, Florin L, Patel HD, Freitag K, Schmidtke M, et al. (2007) Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81: 10970-10980.
27. Day PM, Lowy DR, Schiller JT, (2008) Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol 82: 12565-12568.
28. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, et al. (1997) Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71: 2449-2456.
29. Surviladze Z, Dziduszko A, Ozbun MA, (2012) Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog 8: e1002519.
30. Bienkowska-Haba M, Patel HD, Sapp M, (2009) Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 5: e1000524.
31. Patterson NA, Smith JL, Ozbun MA, (2005) Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol 79: 6838-6847.
32. Bauer PH, Cui C, Liu WR, Stehle T, Harrison SC, et al. (1999) Discrimination between sialic acid-containing receptors and pseudoreceptors regulates polyomavirus spread in the mouse. J Virol 73: 5826-5832.
33. Sapp M, Day PM, (2009) Structure, attachment and entry of polyoma- and papillomaviruses. Virology 384: 400-409.
34. Neu U, Maginnis MS, Palma AS, Stroh LJ, Nelson CD, et al. (2010) Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8: 309-319.
35. Conway MJ, Cruz L, Alam S, Christensen ND, Meyers C, (2011) Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes. PLoS One 6: e16405.
36. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, et al. (2012) Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog 8: e1002657.
37. HIV/AIDS and STD Updates. AIDS Patient Care STDS 25: 265-267.
38. Smith JL, Campos SK, Ozbun MA, (2007) Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol 81: 9922-9931.
39. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M, (2003) Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 77: 12961-12967.
40. Lembo D, Donalisio M, Rusnati M, Bugatti A, Cornaglia M, et al. (2008) Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob Agents Chemother 52: 1374-1381.
41. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83: 2067-2074.
42. Turnbull J, Powell A, Guimond S, (2001) Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11: 75-82.
43. Dasgupta J, Bienkowska-Haba M, Ortega ME, Patel HD, Bodevin S, et al. (2010) Structural basis of oligosaccharide receptor recognition by human papillomavirus. J Biol Chem 286: 2617-2624.
44. Talarico LB, Damonte EB, (2007) Interference in dengue virus adsorption and uncoating by carrageenans. Virology 363: 473-485.
45. Sapp M, Fligge C, Petzak I, Harris JR, Streeck RE, (1998) Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J Virol 72: 6186-6189.
46. Fligge C, Schafer F, Selinka HC, Sapp C, Sapp M, (2001) DNA-induced structural changes in the papillomavirus capsid. J Virol 75: 7727-7731.
47. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT, (2005) Maturation of papillomavirus capsids. J Virol 79: 2839-2846.